clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT04388189 |
P6099 | clinical trial phase | phase IV clinical trial | Q42825046 |
P582 | end time | 2023-05-30 | |
P921 | main subject | (S)-duloxetine | Q411932 |
P4135 | maximum age | 85 | |
P2899 | minimum age | 22 | |
P1132 | number of participants | 200 | |
P4844 | research intervention | bupropion | Q834280 |
duloxetine hydrochloride | Q27116971 | ||
P8005 | research subject recruitment status | not yet recruiting | Q76649614 |
P1813 | short name | LEAP-DB | |
P580 | start time | 2020-06-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion (LEAP-DB): A Multicenter, Randomized, Blinded Outcome Study of EEG-guided Treatment With Duloxetine Versus Bupropion in Adults With Major Depressive Disorder |